Back to news

Jaguar Health Reports Third Quarter 2026 Financials

ACCESSWIRE•16/11/2026•09:00 ET
0

Key Highlights

  • ➤License and grant revenue $1.792M, up 4166.7% year over year
  • ➤Total revenue $2.343M, down 24.0% year over year
  • ➤Net loss $5.830M, improved 39.6% year over year
  • ➤Prescription product revenue $0.5M, down from $3.0M year over year
  • ➤Sales and marketing expense fell to approximately $51,000 after Future Pak licensing

SAN FRANCISCO, CA / ACCESS Newswire / November 16, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (link) ("Jaguar" or the "Company") today reported its consolidated third-quarter 2026 financial results.

2026 THIRD QUARTER COMPANY FINANCIAL RESULTS: * License and Grant Revenue: Effective January 12, 2026, Jaguar entered a U.S. commercial licensing agreement with Woodward Specialty, LLC ("Woodward"), an affiliate of privately held Future Pak, LLC ("Future Pak"). Under the terms of the agreement, Future Pak is now the exclusive U.S. marketer for the Company's Mytesi(®) and Canalevia(®)-CA1 products. The Company remains the manufacturer of Mytesi and Canalevia-CA1, supplying the products to Future Pak at cost-plus terms, and now operates as a distribution entity for Mytesi and Canalevia-CA1 with a primary focus on research and development efforts related to the Company's late-stage development program for its powder-for-oral-solution formulation of crofelemer for rare-disease indications related to intestinal failure in humans. License revenues for the initial $16 million upfront payment, in addition to the $3 million payment for early termination of the Buy-Back Option, under the agreement with Future Pak were recognized by the Company in the first quarter of 2026. As announced in August 2026, Jaguar satisfied the closing conditions required to receive payment of the non-dilutive approximately $1.8 million holdback amount of the upfront fee from Future Pak. Additionally, the Company recognized license fees of $42,000 in the third quarter of 2026 from a securities purchase agreement with a European partner, which was supported by a binding term sheet. Approximately $42,000 of license fees were consistently recognized in each of the quarters of 2025 under this agreement. As of September 30, 2026, the total deferred revenue associated with this contract amounts to $425,000. There was no Federal grant revenue recognized in the third quarter of 2026 for the clinical study related to the treatment of chemotherapy-induced diarrhea ("CID") in dogs and $25,000 in the nine-months ended September 30, 2026. * Prescription Product Revenue, Net: The total net revenue for the Company's prescription products (Mytesi, Gelclair, and Canalevia-CA1) was approximately $0.5 million in the third quarter of 2026, which was comprised primarily of sales of Mytesi at cost-plus to Future Pak. In January 2026, Jaguar entered into a royalty-free license agreement with Future Pak. Under this agreement, all revenues generated in the United States from Mytesi and Canalevia-CA1, effective from January 12, 2026, are directed to Future Pak. Future Pak is privately held and does not report Mytesi sales. The decision to enter a commercial license agreement with Future Pak aligns with Jaguar's strategic focus on advancing the development of its powder-for-oral-solution formulation of crofelemer for rare-disease indications related to intestinal failure in humans. The total net revenue for the Company's prescription products in the second quarter of 2026 was approximately $1.2 million. Compared to the third quarter of 2025, the number of Mytesi bottles the Company sold in the third quarter of 2026 increased significantly and commercial costs were substantially decreased. Prescription products net revenue in the third quarter of 2025, when the Company had a salesforce and was focused on commercial sales of Mytesi, was approximately $3.0 million. * Neonorm(™): Revenues for the non-prescription Neonorm products were consistent and minimal for the third quarters of 2026 and 2025.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in